Hussman Strategic Advisors Inc. Buys 10,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hussman Strategic Advisors Inc. raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 100.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,000 shares of the medical equipment provider's stock after purchasing an additional 10,500 shares during the period. Hussman Strategic Advisors Inc.'s holdings in Lantheus were worth $2,050,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Lantheus by 3.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after buying an additional 400 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of Lantheus by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after buying an additional 215 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after buying an additional 127,424 shares in the last quarter. Pictet Asset Management Holding SA raised its position in shares of Lantheus by 12.1% during the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after buying an additional 1,113 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Lantheus by 1,196.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock valued at $32,817,000 after buying an additional 310,301 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on LNTH shares. Truist Financial lowered their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. William Blair restated a "market perform" rating on shares of Lantheus in a research report on Wednesday. Finally, B. Riley lowered their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $131.20.

Lantheus Trading Down 4.6%

NASDAQ:LNTH traded down $3.42 during trading hours on Friday, reaching $70.18. The company's stock had a trading volume of 1,351,740 shares, compared to its average volume of 980,999. The firm has a market capitalization of $4.86 billion, a price-to-earnings ratio of 19.94 and a beta of 0.12. The firm has a 50-day simple moving average of $78.80 and a 200-day simple moving average of $89.44. Lantheus Holdings, Inc. has a 1 year low of $69.12 and a 1 year high of $118.71. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the business earned $1.69 EPS. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.